Clinical Trials Browser

Mesothelioma, Malignant

NCT05429866 2023-03-08

Immunological Variables Associated to ICI Toxicity in Cancer Patients

BreastDermatologicGastrointestinalGenitourinaryHead & NeckOther solid neoplasmThoracic

Mesothelioma, Malignant, Urinary Bladder Neoplasms, Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Gastrointestinal Neoplasms, Head and Neck Neoplasms, Carcinoma, Hepatocellular, Melanoma, Carcinoma, Merkel Cell, Small Cell Lung Carcinoma

Clinical Trials

MiST

Immunological Variables Associated to ICI Toxicity in Cancer Patients

Pleurectomy/ Decortication (P/D) Preceded or Followed by Chemotherapy in Patients With Early Stage MPM

MTG201 Plus Nivolumab in Patients With Relapsed Pleural Mesothelioma

Neoadjuvant Toripalimab Combined With Chemotherapy in the Treatment of Malignant Pleural Mesothelioma

uPAR-PET for Prognostication in Patients With Non-small Cell Lung Cancer, Malignant Pleural Mesothelioma and Large Cell Neuroendocrine Carcinoma of the Lung

A Study of Tremelimumab Combined With the Anti-PD-L1 MEDI4736 Antibody in Malignant Mesothelioma (NIBIT-MESO-1)

Four Versus Six Cycles of Pemetrexed/Platinum for MPM

ADAM

Surgery, Chemotherapy, and Radiation Therapy in Treating Patients With Peritoneal Cancer

Palliative Therapy With or Without Chemotherapy in Treating Patients With Malignant Mesothelioma

The Anti-CTLA-4 Monoclonal Antibody Tremelimumab in Malignant Mesothelioma

A Clinical Study With Tremelimumab as Monotherapy in Malignant Mesothelioma

Palliative Treatment With Liposomal Doxorubicin Plus Cisplatin for Patients With Malignant Pleural Mesothelioma